Investment Analysts’ Weekly Ratings Changes for UiPath (PATH)

A number of research firms have changed their ratings and price targets for UiPath (NYSE: PATH):

• 9/6/2024 – UiPath had its “sector perform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $16.00 price target on the stock.
• 9/6/2024 – UiPath had its price target raised by analysts at DA Davidson from $13.00 to $15.00. They now have a “neutral” rating on the stock.
• 9/6/2024 – UiPath had its price target raised by analysts at Bank of America Co. from $16.00 to $18.00. They now have a “neutral” rating on the stock.
• 9/6/2024 – UiPath had its price target raised by analysts at BMO Capital Markets from $14.00 to $15.00. They now have a “market perform” rating on the stock.
• 9/6/2024 – UiPath had its price target raised by analysts at Evercore ISI from $13.00 to $16.00. They now have an “in-line” rating on the stock.
• 9/6/2024 – UiPath had its price target lowered by analysts at TD Cowen from $17.00 to $16.00. They now have a “hold” rating on the stock.
• 9/6/2024 – UiPath had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
• 9/6/2024 – UiPath had its price target raised by analysts at Barclays PLC from $14.00 to $15.00. They now have an “equal weight” rating on the stock.
• 9/6/2024 – UiPath had its “equal weight” rating reaffirmed by analysts at Morgan Stanley. They now have a $15.00 price target on the stock.
• 9/6/2024 – UiPath had its price target raised by analysts at Wells Fargo & Company from $14.00 to $15.00. They now have an “equal weight” rating on the stock.
• 8/19/2024 – UiPath had its price target lowered by analysts at Barclays PLC from $16.00 to $14.00. They now have an “equal weight” rating on the stock.

UiPath Trading Up 3.4 %

Shares of UiPath stock opened at $12.91 on Tuesday. The firm has a fifty day simple moving average of $12.13 and a 200-day simple moving average of $15.76. UiPath Inc. has a 1-year low of $10.37 and a 1-year high of $27.87. The stock has a market capitalization of $7.39 billion, a price-to-earnings ratio of -80.69 and a beta of 0.87.

UiPath (NYSE:PATH) last issued its quarterly earnings results on Thursday, September 5th. The healthcare company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.01. UiPath had a negative return on equity of 3.98% and a negative net margin of 8.13%. The company had revenue of $316.00 million for the quarter, compared to the consensus estimate of $303.69 million. During the same period last year, the business posted ($0.09) earnings per share. The firm’s revenue was up 10.0% compared to the same quarter last year. As a group, research analysts predict that UiPath Inc. will post -0.23 earnings per share for the current year.

Insiders Place Their Bets

In other UiPath news, CFO Ashim Gupta sold 47,671 shares of the firm’s stock in a transaction on Friday, September 13th. The shares were sold at an average price of $12.07, for a total value of $575,388.97. Following the sale, the chief financial officer now directly owns 849,917 shares in the company, valued at approximately $10,258,498.19. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 22.37% of the company’s stock.

Institutional Investors Weigh In On UiPath

Institutional investors have recently bought and sold shares of the business. Intech Investment Management LLC boosted its stake in UiPath by 3.1% in the 4th quarter. Intech Investment Management LLC now owns 14,324 shares of the healthcare company’s stock valued at $356,000 after buying an additional 426 shares in the last quarter. Global Financial Private Client LLC boosted its stake in UiPath by 9.3% in the 1st quarter. Global Financial Private Client LLC now owns 6,471 shares of the healthcare company’s stock valued at $144,000 after buying an additional 551 shares in the last quarter. Principal Financial Group Inc. increased its position in shares of UiPath by 1.7% during the 1st quarter. Principal Financial Group Inc. now owns 36,772 shares of the healthcare company’s stock worth $834,000 after purchasing an additional 622 shares in the last quarter. GAMMA Investing LLC increased its position in shares of UiPath by 40.2% during the 1st quarter. GAMMA Investing LLC now owns 2,204 shares of the healthcare company’s stock worth $50,000 after purchasing an additional 632 shares in the last quarter. Finally, Lindbrook Capital LLC increased its position in shares of UiPath by 46.0% during the 1st quarter. Lindbrook Capital LLC now owns 2,027 shares of the healthcare company’s stock worth $46,000 after purchasing an additional 639 shares in the last quarter. Institutional investors and hedge funds own 62.50% of the company’s stock.

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.